Weekly signal · SMMT · Healthcare

Summit Therapeutics PLC (SMMT) cools with four-week gain still at 31.5%

The biotechnology stock’s weekly setup is mixed, with a flat latest week set against a still-strong medium-term advance.

Summit Therapeutics PLC
Latest17.55 USD
1W move-0.3%
Volume0.8x
TrendInactive
Biotechnology lab and market data screen representing Summit Therapeutics weekly stock analysis.

Market update

What happened

Summit Therapeutics PLC (SMMT) closed the latest week at 17.55 USD, down -0.3% in the weekly price path over 52 weeks. The move paused recent momentum without erasing the broader advance in the NASDAQ-listed Healthcare name.

The confirming evidence was limited. Market Dynamics showed only mild confirmation at 0.3, while the trend signal was inactive and Relative Strength stood at -7.4. Weekly volume was 20.7 million shares, below the 24.5 million 13-week average.

Continue your research

Explore SMMT across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

SMMT coverage

Evidence context